Stroke is one of the leading causes of death and disability world-wide. Dr. Tymianski, Head of Neurosurgery at TWH and Senior Scientist at TWRI, has dedicated two decades of his career to stroke research. Through this work, he has developed a promising new drug, NA-1, that may limit damage after stroke.
On Friday September 12th 2014, Brain Canada announced that it will provide $10 million to carry out a Phase III trial (the FRONTIER trial) that aims to test the ability of NA-1 to reduce tissue damage after stroke. As part of this trial, paramedics will administer the drug to 518 stroke patients in Toronto, Peel Region and Vancouver starting January 2015.
Previously, a Phase II trial for NA-1 (the ENACT trial) was carried out in collaboration with Dr. Michael Hill and colleagues at the University of Calgary in Alberta. The results, published in The Lancet Neurology, showed the safety and efficacy of the drug at reducing the number of new strokes in patients undergoing an endovascular repair procedure.
Image caption: Announcement of FRONTIER trial funding at St. Michael’s Hospital. Photo credit: St. Michael’s Hospital
Comments